



Casgevvy® Gene Therapy Treatment Centers

ETS Program Reference Guide

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions.

Programs listed here are authorized treatment centers (ATCs) for which ETS either may have contracted rates in place or may have access to rates through single case agreements for **Casgevvy** (exagamglogene autotemcel) which is approved to treat **sickle cell disease** and **transfusion-dependent beta thalassemia**.

For assistance with your member referral or for more information, contact ETS at 877-445-4822 or by email at clientservices@emergingtherapies.com.

▼ Denotes facilities at which ETS has gene therapy rates in place.

State	City	Program Listing
Arizona	Phoenix	Phoenix Children's Hospital
Arkansas	Little Rock	Arkansas Children's Hospital
California	Los Angeles	Children's Hospital Los Angeles ▼
	Los Angeles	U.C.L.A. Medical Center
	Duarte	City of Hope
Colorado	Denver	Children's Hospital Colorado
Delaware	Wilmington	Alfred I. duPont Hospital for Children ▼
Florida	Gainesville	UF Health Shands Hospital
	Jacksonville	Mayo Clinic
	Miami	Jackson Memorial Hospital
	Orlando	AdventHealth Orlando
Georgia	Atlanta	Children's Healthcare of Atlanta
		Emory Healthcare
	Augusta	Wellstar MCG Health
Illinois	Chicago	Ann & Robert H. Lurie Children's Hospital of Chicago
		Northwestern Memorial Hospital
Kansas	Kansas City	University of Kansas Hospital ▼
Maryland	Baltimore	University of Maryland Medical Center ▼
		Johns Hopkins Hospital ▼
Massachusetts	Boston	Boston Children's Hospital
		Dana-Farber Cancer Institute
		Massachusetts General Hospital
Michigan	Grand Rapids	Corewell Health Helen Devos Children's Hospital – Corewell Health Grand Rapids Hospitals ▼
	Detroit	Henry Ford Health System
	Ann Arbor	University of Michigan Medical Center ▼
Minnesota	Minneapolis	M Health Fairview University of Minnesota Medical Center
Mississippi	Jackson	University of Mississippi Medical Center ▼



Casgevvy® Gene Therapy Treatment Centers

ETS Program Reference Guide

▼ Denotes facilities at which ETS has gene therapy rates in place.

Missouri	St. Louis	Barnes Jewish Hospital ▼
		St. Louis Children's Hospital ▼
	Kansas City	Children's Mercy Hospital ▼
Nebraska	Omaha	Nebraska Medical Center
New York	New York	Memorial Sloan-Kettering Cancer Center
		Mount Sinai Hospital
	Rochester	Strong Memorial Hospital
	Buffalo	Roswell Park Cancer Institute
North Carolina	Durham	Duke University Hospital
	Chapel Hill	University of North Carolina Hospitals
Ohio	Cincinnati	Cincinnati Children's Hospital Medical Center ▼
	Cleveland	Cleveland Clinic
	Columbus	James Cancer Hospital at Ohio State University
		Nationwide Children's Hospital
Oregon	Portland	Oregon Health & Science University ▼
Pennsylvania	Philadelphia	Children's Hospital of Philadelphia ▼
		Thomas Jefferson University Hospital
South Carolina	Charleston	Medical University of South Carolina ▼
Tennessee	Nashville	Children's Hospital at TriStar Centennial
		Vanderbilt University Medical Center
Texas	Dallas	Children's Medical Center of Dallas
		Medical City Dallas
	San Antonio	Methodist Healthcare System San Antonio
	Houston	Texas Children's Hospital ▼
Washington	Seattle	Seattle Children's Hospital ▼
	Seattle	Fred Hutchinson Cancer Center-Fred Hutchinson
Wisconsin	Milwaukee	Children's Hospital of Wisconsin
		Froedtert and Medical College of Wisconsin

© 2026 Emerging Therapy Solutions, Inc. All Rights Reserved. AP-10602. ETS is a trademark of Emerging Therapy Solutions, Inc. All other trademarks referenced herein are the property of their respective owners. The information provided here is believed to be accurate as of the listed document production date and is based on information currently available to us. Because facility and program changes may occur, please confirm details with our ETS clinical consultants at 877-445-4822 or clientservices@emergingtherapies.com. Please note that coverage for any indicated services is subject to applicable plan documents. 9/10/2026